Abstract
Cladribine is a highly effective, recently available treatment in multiple sclerosis. This case report describes a patient with COVID-19 infection during second year treatment with cladribine. The infection was mild and she was able to mount an adequate immune response with detectable antibodies three months later.
Keywords: COVID-19; Cladribine; Multiple sclerosis; SARS-CoV-2.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, multiple sclerosis, Cladribine, 【초록키워드】 Treatment, SARS-CoV-2, immune response, multiple sclerosis, antibody, Infection, Case report, COVID-19 infection, Mild, Cladribine, Multiple, patient with COVID-19, effective, detectable, 【제목키워드】 Treatment, Cladribine, Normal antibody,
【저자키워드】 COVID-19, SARS-CoV-2, multiple sclerosis, Cladribine, 【초록키워드】 Treatment, SARS-CoV-2, immune response, multiple sclerosis, antibody, Infection, Case report, COVID-19 infection, Mild, Cladribine, Multiple, patient with COVID-19, effective, detectable, 【제목키워드】 Treatment, Cladribine, Normal antibody,
{{{ 추상적인 }}}
클라드리빈은 다발성 경화증에서 매우 효과적이고 최근에 사용 가능한 치료법입니다. 이 증례 보고서는 2년차 클라드리빈 치료 중 COVID-19 감염 환자에 대해 설명합니다. 감염은 경미했고 그녀는 3개월 후에 검출 가능한 항체로 적절한 면역 반응을 일으킬 수 있었습니다.
{{ 키워드: }} 코로나19; 클라드리빈; 다발성 경화증; 사스 코로나바이러스 2.